312 related articles for article (PubMed ID: 26889831)
1. Therapeutic vaccines for prostate cancer: recent advances and future directions.
Strauss J; Madan RA
Expert Rev Vaccines; 2016 Jul; 15(7):907-14. PubMed ID: 26889831
[TBL] [Abstract][Full Text] [Related]
2. Integrating Immunotherapies in Prostate Cancer.
Strauss J; Madan RA
Curr Oncol Rep; 2015 Oct; 17(10):45. PubMed ID: 26275784
[TBL] [Abstract][Full Text] [Related]
3. Prospects for the future of prostate cancer vaccines.
Madan RA; Gulley JL
Expert Rev Vaccines; 2016; 15(3):271-4. PubMed ID: 26560494
[TBL] [Abstract][Full Text] [Related]
4. Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.
Antonarakis ES; Drake CG
Curr Opin Oncol; 2012 May; 24(3):258-65. PubMed ID: 22410456
[TBL] [Abstract][Full Text] [Related]
5. Combining immunotherapies for the treatment of prostate cancer.
Redman JM; Gulley JL; Madan RA
Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era.
Arlen PM; Wood LV
Expert Rev Vaccines; 2012 Mar; 11(3):287-302. PubMed ID: 22380822
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for prostate cancer: recent developments and future challenges.
Schweizer MT; Drake CG
Cancer Metastasis Rev; 2014 Sep; 33(2-3):641-55. PubMed ID: 24477411
[TBL] [Abstract][Full Text] [Related]
8. Current vaccination strategies for prostate cancer.
Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
[TBL] [Abstract][Full Text] [Related]
9. Preclinical and clinical development of DNA vaccines for prostate cancer.
Colluru VT; Johnson LE; Olson BM; McNeel DG
Urol Oncol; 2016 Apr; 34(4):193-204. PubMed ID: 24332642
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer vaccines in clinical trials.
Lubaroff DM
Expert Rev Vaccines; 2012 Jul; 11(7):857-68. PubMed ID: 22913261
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy and immunotherapy combination in advanced prostate cancer.
Slovin S
Clin Adv Hematol Oncol; 2012 Feb; 10(2):90-100. PubMed ID: 22402350
[TBL] [Abstract][Full Text] [Related]
12. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
McKarney I
Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
[TBL] [Abstract][Full Text] [Related]
13. A New Era of Immunotherapy in Prostate Cancer.
Pizzola C; Rizvi SM; Joshi M
Curr Mol Pharmacol; 2016; 9(3):217-225. PubMed ID: 26177645
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in immunotherapy for the treatment of prostate cancer.
Sonpavde G; Agarwal N; Choueiri TK; Kantoff PW
Expert Opin Biol Ther; 2011 Aug; 11(8):997-1009. PubMed ID: 21675925
[TBL] [Abstract][Full Text] [Related]
15. Development of novel immune interventions for prostate cancer.
Agarwal N; Padmanabh S; Vogelzang NJ
Clin Genitourin Cancer; 2012 Jun; 10(2):84-92. PubMed ID: 22409862
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in prostate cancer: emerging strategies against a formidable foe.
Bilusic M; Heery C; Madan RA
Vaccine; 2011 Sep; 29(38):6485-97. PubMed ID: 21741424
[TBL] [Abstract][Full Text] [Related]
17. Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.
Madan RA; Gulley JL; Kantoff PW
Cancer J; 2013; 19(1):50-8. PubMed ID: 23337757
[TBL] [Abstract][Full Text] [Related]
18. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic vaccines for prostate cancer.
Tarassoff CP; Arlen PM; Gulley JL
Oncologist; 2006 May; 11(5):451-62. PubMed ID: 16720845
[TBL] [Abstract][Full Text] [Related]
20. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.
Gardner TA; Elzey BD; Hahn NM
Hum Vaccin Immunother; 2012 Apr; 8(4):534-9. PubMed ID: 22832254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
